semaglutide iih GLP-1's and : r/iih Large-Scale Study Highlights Therapeutic Benefits

Chen X, Hou X, Bai D, et al

The most commonly reported side effects in Phase 2 trials were gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and decreased appetite

The article suggests it may, describing most injectable GLP-1 agonists as large peptides that poorly cross biological barriers, with larger peptides less likely to enter milk

Any significant weight loss, regardless of method, results in some lean mass loss

Endothelial Progenitor Cells as Pathogenetic and Diagnostic Factors, and Potential Targets for GLP-1 in Combination with Metabolic Syndrome and Chronic Obstructive Pulmonary Disease